Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis - Full Text View

Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis

This study has been completed.

Sponsors and Collaborators:	National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Ohio State University
Information provided by:	National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:	NCT00004305

Purpose

OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA glomerulonephritis (IgA-N).

II. Compare genetic anomalies of these key components in immune complex processing and clearance between juvenile vs adult onset IgA-N vs normal controls.

Condition

IGA Glomerulonephritis

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment:	105
Study Start Date:	January 1998

Detailed Description:

PROTOCOL OUTLINE:

Participants undergo qualitative genetic analysis of complement-related proteins. Studies include: genomic re-arrangement of 4-gene unit, C4 DNA sequence and RNA expression, type-1 complement receptor DNA sequence, Fc-gamma receptor IIIA isoform analysis, classical and alternative complement activation pathway assays, plasma C4 and C4d protein levels, and immunoglobulin patterns in glomerular deposits.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

IgA glomerulonephritis

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004305

Locations


United States, Ohio
	Ohio State University
	Columbus, Ohio, United States

Sponsors and Collaborators

National Center for Research Resources (NCRR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Ohio State University

Investigators


Study Chair:	Lee A. Hebert	Ohio State University

More Information

Study ID Numbers:	199/11791, OSU-94H0338
First Received:	October 18, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004305
Health Authority:	United States: Federal Government